SELLAS Life Sciences Group, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SELLAS Life Sciences Group, Inc. (SLS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.01M, a 102.59% increase year-over-year.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $798.00K, a 58.02% increase year-over-year.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $447.00K, a 19.84% increase year-over-year.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $503.00K, a 32.02% increase year-over-year.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.96M, a 25.06% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.56M, a 25.31% decline from fiscal 2023.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.09M, a 21.32% increase from fiscal 2022.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.73M, a 70.72% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-11 | $1.81M 10-Q · filed 2026-08-11 | $2.26M derived: sum of 3 quarters · filed 2026-08-11 | $2.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $798.00K 10-Q · filed 2026-05-12 | $1.25M derived: sum of 2 quarters · filed 2026-05-12 | $1.75M derived: sum of 3 quarters · filed 2026-05-12 | $2.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $950.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.45M derived: sum of 3 quarters · filed 2026-08-11 | $1.96M 10-K · filed 2026-03-19 |
| 2025-09-30 | $503.00K 10-Q · filed 2025-11-12 | $1.00M derived: sum of 2 quarters · filed 2026-08-11 | $1.51M 10-Q · filed 2025-11-12 | $1.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $501.00K 10-Q · filed 2026-08-11 | $1.01M 10-Q · filed 2026-08-11 | $1.38M derived: sum of 3 quarters · filed 2026-08-11 | $1.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $505.00K 10-Q · filed 2026-05-12 | $878.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.26M derived: sum of 3 quarters · filed 2026-05-12 | $1.59M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $754.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.09M derived: sum of 3 quarters · filed 2026-03-19 | $1.56M 10-K · filed 2026-03-19 |
| 2024-09-30 | $381.00K 10-Q · filed 2025-11-12 | $715.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.19M 10-Q · filed 2025-11-12 | $1.69M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $334.00K 10-Q · filed 2025-08-12 | $810.00K 10-Q · filed 2025-08-12 | $1.31M derived: sum of 3 quarters · filed 2025-08-12 | $1.85M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $476.00K 10-Q · filed 2025-05-13 | $973.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.52M derived: sum of 3 quarters · filed 2025-05-13 | $2.03M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.04M derived: sum of 2 quarters · filed 2025-03-20 | $1.55M derived: sum of 3 quarters · filed 2025-03-20 | $2.09M 10-K · filed 2025-03-20 |
| 2023-09-30 | $543.00K 10-Q · filed 2024-11-13 | $1.06M derived: sum of 2 quarters · filed 2024-11-13 | $1.60M 10-Q · filed 2024-11-13 | $2.04M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $514.00K 10-Q · filed 2024-08-13 | $1.05M 10-Q · filed 2024-08-13 | $1.50M derived: sum of 3 quarters · filed 2024-08-13 | $1.96M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $540.00K 10-Q · filed 2024-05-14 | $986.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.44M derived: sum of 3 quarters · filed 2024-05-14 | $1.89M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $901.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.35M derived: sum of 3 quarters · filed 2024-03-28 | $1.73M 10-K · filed 2024-03-28 |
| 2022-09-30 | $455.00K 10-Q · filed 2023-11-09 | $905.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.28M 10-Q · filed 2023-11-09 | $1.57M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $450.00K 10-Q · filed 2023-08-10 | $825.00K 10-Q · filed 2023-08-10 | $1.11M derived: sum of 3 quarters · filed 2023-08-10 | $1.39M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $375.00K 10-Q · filed 2023-05-11 | $663.00K derived: sum of 2 quarters · filed 2023-05-11 | $938.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $563.00K derived: sum of 2 quarters · filed 2023-03-16 | $827.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.01M 10-K · filed 2023-03-16 |
| 2021-09-30 | $275.00K 10-Q · filed 2022-11-14 | $539.00K derived: sum of 2 quarters · filed 2022-11-14 | $723.00K 10-Q · filed 2022-11-14 | $864.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $264.00K 10-Q · filed 2022-08-11 | $448.00K 10-Q · filed 2022-08-11 | $589.00K derived: sum of 3 quarters · filed 2022-08-11 | $735.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $184.00K 10-Q · filed 2022-05-12 | $325.00K derived: sum of 2 quarters · filed 2022-05-12 | $471.00K derived: sum of 3 quarters · filed 2022-05-12 | $617.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $287.00K derived: sum of 2 quarters · filed 2022-03-31 | $433.00K derived: sum of 3 quarters · filed 2022-03-31 | $578.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $146.00K 10-Q · filed 2021-11-12 | $292.00K derived: sum of 2 quarters · filed 2021-11-12 | $437.00K 10-Q · filed 2021-11-12 | $584.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $146.00K 10-Q · filed 2021-08-12 | $291.00K 10-Q · filed 2021-08-12 | $438.00K derived: sum of 3 quarters · filed 2021-08-12 | $553.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $145.00K 10-Q · filed 2021-05-13 | $292.00K derived: sum of 2 quarters · filed 2021-05-13 | $407.00K derived: sum of 3 quarters · filed 2021-05-13 | $533.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $262.00K derived: sum of 2 quarters · filed 2021-03-23 | $388.00K derived: sum of 3 quarters · filed 2021-03-23 | $573.00K 10-K · filed 2021-03-23 |
| 2019-09-30 | $115.00K 10-Q · filed 2020-11-13 | $241.00K derived: sum of 2 quarters · filed 2020-11-13 | $426.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $126.00K 10-Q · filed 2020-08-13 | $311.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $185.00K 10-Q · filed 2020-05-14 | |||
| 2018-09-30 | $136.00K 10-Q · filed 2019-11-14 | $284.00K 10-Q · filed 2019-11-14 | ||
| 2014-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $63.00K derived: sum of 2 quarters · filed 2014-11-05 | $138.00K 10-Q · filed 2014-11-05 | $715.00K derived: sum of 4 quarters · filed 2015-12-04 |
| 2014-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $158.00K 10-Q · filed 2014-08-11 | $735.00K derived: sum of 3 quarters · filed 2015-12-04 | |
| 2014-03-31 | $75.00K 10-Q · filed 2014-05-06 | $652.00K derived: sum of 2 quarters · filed 2015-12-04 | ||
| 2013-12-31 | $577.00K derived: 8-K 12 month − 10-Q/A 9 month · filed 2015-12-04 | $644.00K 8-K · filed 2015-12-04 | ||
| 2013-09-30 | $67.00K 10-Q/A · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |